Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 -- More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferonβ-1a (IFNβ-1a) treatment, and the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news